How safe is off-label use of imiquimod in oral lesions?

Ana Luisa Amaral Bashir Abdulgader LwaleedJerry Elmer BouquotSérgio Araújo Andrade

Published in: Evidence-based dentistry (2024)

The study elucidated the off-label use of imiquimod in oral pathologies, whether potentially malignant, cancerous, autoimmune, or associated with HPV infection. However, it was observed that further research is warranted for the development of a specific formulation for the oral mucosa, ensuring the drug's sustained presence at its active site of action without interference from saliva and minimizing potential side effects.

Keyphrases

drug delivery
high grade
risk assessment
human health
adverse drug
electronic health record